Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 11, 2005, Pages 755-767

  Yu, D Tony ^a,b   Peterson, Josh F ^d   Seger, Diane L ^b   Gerth, William C ^c   Bates, David W ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adverse drug events; Azole antifungals; Drug interactions; Fluconazole; Itraconazole; Ketoconazole

Indexed keywords

AMLODIPINE; AMPHOTERICIN; ANTACID AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; CLONAZEPAM; CYCLOSPORIN; FLUCONAZOLE; FLURAZEPAM; ITRACONAZOLE; KETOCONAZOLE; LOSARTAN; METHYLPREDNISOLONE; MIDAZOLAM; NIFEDIPINE; NIZATIDINE; OMEPRAZOLE; PHENYTOIN; PREDNISONE; PYRROLE DERIVATIVE; RANITIDINE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; ZOLPIDEM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER; COHORT ANALYSIS; DRUG FEVER; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMIC MYCOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIFUNGAL AGENTS; AZOLES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES;

EID: 23344449482     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1073     Document Type: Review

References (100)

1. Flockhart DA, Yasuda SU, Honig P, et al. Preventable adverse drug reactions: a focus on drug interactions. FDA/Center for Drug Evaluation and Research and Centers for Education and Research on Therapeutics. Available at http://www.fda.gov/cder/drug/drugReactions/. [Accessed 21 January 2004].
2. Bates DW, O'Neil AC, Boyle D, et al. Potential identifiability and preventability of adverse events using information systems. J Am Med Informatics Assoc 1994; 1: 404-411.
3. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events: ADE Prevention Study Group. JAMA 1995; 274: 35-43.
4. Gandhi TK, Weingart SN, Boras J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348: 1556-1564.
5. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-59.
6. Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency department visits at and HMO medical center. Am J Health Syst Pharm 1996; 53: 1416-1422.
7. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994; 14: 509-513.
8. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165-174.
9. Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother 1994; 38: 326-329.
10. Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35: 1765-1771.
11. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915-928.
12. Koks CH, Crommentuyn KM, Hoetelmans RM, et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001; 51: 631-635.
13. Hilbert J, Messig M, Kaye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 2001; 98: 218-223.
14. Mathis AS, DiRenzo T, Friedman GS, et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001; 71: 1069-1075.
15. Niemi M, Backman JT, Neuvonen M, et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69: 194-200.
16. Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225-229.
17. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43: 509-514.
18. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obstet Gynecol 1998; 178: 300-304.
19. De Wit S, Debier M, De Smet M, et al. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42: 223-227.
20. Brockmeyer NH, Tillmann I, Mertins L, et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997; 2: 377-383.
21. Cato A, III, Cao G, Hsu A, et al. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997; 25: 1104-1106.
22. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 51: 415-419.
23. Niemi M, Neuvonen M, Juntti-Patinen L, et al. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther 2003; 74: 25-31.
24. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-450.
25. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000; 68: 487-494.
26. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000; 56: 57-60.
27. Palkama VJ, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers. Br J Anaesth 1999; 83: 659-661.
28. Kivisto KT, Lamberg TS, Neuvonen PJ. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 1999; 84: 94-97.
29. Auclair B, Berning SE, Huitt GA, Peloquin CA. Potential interaction between itraconazole and clarithromycin. Pharmacotherapy 1999; 19: 1439-1444.
30. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48: 829-838.
31. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 1998; 139: 269-273.
32. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
33. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-58.
34. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53.
35. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65.
36. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001; 41: 1043-1054.
37. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001; 57: 115-121.
38. Kosoglou T, Salfi M, Lim JM, et al. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50: 581-589.
39. Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000; 68: 637-646.
40. Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999; 19: 1378-1384.
41. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46: 30-39.
42. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-516.
43. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996; 41: 319-323.
44. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993; 16: 400-403.
45. Mathis AS, Friedman GS. Coadministration of digoxin with itraconazole in renal transplant recipients. Am J Kidney Dis 2001; 37: E18.
46. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000; 18: 227-229.
47. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 1201-1206.
48. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-1518.
49. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191-193.
50. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29-34.
51. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280: 1311-1316.
52. Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10: 199-205.
53. Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999; 6: 313-321.
54. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109: 87-94.
55. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267-270.
56. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285: 2114-2120.
57. Drug Interaction Facts (updated July 2002). Facts and Comparisons, St. Louis, Missouri.
58. MICROMEDEX Healthcare Series (vol. 118 expires 12/ 2003). MICROMEDEX: Greenwood Village, Colorado.
59. SAS Procedures Guide, Release 6.12 Edition. SAS Institute, Inc.: Cary, NC, 1996.
60. Beers MH, Storrie M, Lee G. Potential adverse drug interactions in the emergency room. An issue in the quality of care. Ann Intern Med 1990; 112: 61-64.
61. Herr RD, Caravati EM, Tyler LS, et al. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 1992; 21: 1331-1336.
62. Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321-1329.
63. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036-3039.
64. 2002 Report to the Nation: Improving Public Health Through Human Drugs, FDA/Center for Drug Evaluation and Research. Last Updated: May 14, 2003. Available at http://www.fda.gov/cder/reports/rtn/2002/rtn2002-3.HTM. [Accessed 18 November 2003].
65. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18: 83-97.
66. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141: 26-32.
67. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 2000; 34: 1406-1409.
68. Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. Br Med J 1993; 306: 186.
69. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-1703.
70. Bosque E. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. Ann Intern Med 2001; 134: 427.
71. Vanier KL, Mattiussi AJ, Johnston DL. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol 2003; 25: 403-404.
72. Main KM, Skov M, Sillesen IB, et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient. Acta Paediatr 2002; 91: 1008-1011.
73. Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002; 57: 749-750.
74. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002; 23: 148-153.
75. Todd JR, Arigala MR, Penn RL, King JW. Possible clinically significant interaction of itraconazole plus rifampin. Aids Patient Care STDS 2001; 15: 505-510.
76. Cadle RM, Zenon GJ, III, Rodriguez-Barradas MC, Hamill RJ. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 191-195.
77. Wakasugi H, Ishizuka R, Koreeda N, et al. Effect of itraconazole on digoxin clearance in patients with congestive heart failure. J Pharm Soc Jpn 2000; 120: 807-811.
78. Newberry DL, Bass SN, Mbanefo CO. A fluconazole/ amitriptyline drug interaction in three male adults. Clin Infect Dis 1997; 24: 270-271.
79. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37: 1032-1035.
80. Maxa JL, Melton LB, Ogu CC, et al. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 2002; 36: 820-823.
81. Itakura H, Vaughn D, Haller DG, O'Dwyer PJ. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 2003; 169: 613.
82. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-665.
83. Gondo H, Okamura C, Osaki K, et al. Acquired Pelger-Huet anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1255-1257.
84. Furlan V, Parquin F, Penaud JF, et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998; 30: 187-188.
85. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993; 13: 508-509.
86. Allison EJ, Jr, McKinney TJ, Langenberg JN. Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med 2002; 9: 175-177.
87. Mootha W, Schluter ML, Das A. Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol 2002; 120: 94-95.
88. Tailor SA, Gupta AK, Walker SE, Shear NH. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350-352.
89. Nair DR, Morris HH. Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother 1999; 33: 790-792.
90. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228.
91. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-633.
92. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000-1004.
93. Kowalsky SF. Drug interactions with fluconazole. Pharmacotherapy 1990; 10: t-173S.
94. Diflucan (fluconazole tablets, fluconazole injection, and fluconazole for oral suspension), Pfizer, Inc. Revised June 2003. Available at http://www.pfizer.com/download/uspi_diflucan.pdf. [Accessed 6 October 2003].
95. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med 1999; 131: 797.
96. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother 2001; 35: 432-434.
97. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 2002; 22: 1632-1637.
98. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
99. Bradbury BD, Jick SS. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 2002; 22: 697-700.
100. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602.